Farxiga

News

AZ closes on Forxiga kidney disease label in EU after nod fr...

AstraZeneca's fast-growing SGLT2 inhibitor Forxiga could soon get a further boost from approval in the EU as a treatment for chronic kidney disease (CKD) in adults with and without type-2 d

News

Farxiga faces first heart failure rival as EU OKs Boehringer...

AstraZeneca's SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will now have to share the market with Boehringer Ingelheim and Eli Lil

News

AstraZeneca's Farxiga claims first SGLT2 kidney disease OK f...

AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to gather even more momentum after claiming FDA approval in chronic kidney disea

News

AstraZeneca's Farxiga fails phase 3 COVID-19 test

Hope that AstraZeneca's diabetes and heart failure drug Farxiga might treat patients hospitalised with COVID-19 have been dashed after the drug failed to make an impact in a phase 3 trial.

News

Boehringer, Lilly’s Jardiance tries to match AZ’s Farxiga wi...

Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabe

News